Gujarat Themis Biosyn sees pledge release on 1.51% (16.5 lakh) of its shares

What the filing disclosed

On 20 July 2026, Themis Medicare Limited submitted a revised disclosure under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing informs that a pledge on 16,50,000 equity shares of Gujarat Themis Biosyn Limited – equivalent to 1.51 % of the target’s total share capital – was released on 8 July 2026. The release was undertaken by Themis Medicare, the promoter of the target, and was motivated by the repayment of a loan.

"Themis Medicare Limited released a pledge on 16,50,000 shares of Gujarat Themis Biosyn Limited on 08/07/2026, representing 1.51 % of the total share capital."

The disclosure is a regulatory requirement whenever a promoter creates, releases or invokes an encumbrance on shares of a listed entity. By filing the revised statement, Themis Medicare complies with SEBI’s mandate to keep the market informed of any change in the encumbrance status of promoter holdings.

Details of the pledge release

• Promoter’s holding: As of the reporting date, Themis Medicare owned 2,27,74,847 shares of Gujarat Themis Biosyn, amounting to 20.90 % of the target’s equity.
• Encumbrance before release: The same promoter had pledged 16,50,000 shares (1.51 % of total capital) in favour of Jio Credit Limited.
• Event type: The filing records a release of the pledged shares, not a creation or invocation.
• Date of release: The pledge was released on 8 July 2026.
• Reason: The release was undertaken to repay a loan, indicating that the pledged shares were collateral for a borrowing arrangement.
• Post‑event status: After the release, no shares remain encumbered by Themis Medicare in Gujarat Themis Biosyn; the column for “Number % of share capital” under “Name of the entity in whose favour shares encumbered” shows NIL.

The filing also reiterates the corporate relationship details, including the corporate office addresses of both entities, the CIN of Gujarat Themis Biosyn (L24110GJ1969PLC001590), and the contact information of the Managing Director & CEO, Dr. Sachin D. Patel.

Regulatory filing under SEBI Regulation 31

Regulation 31 of the SEBI (SAST) Regulations, 2011 obliges promoters, persons acting in concert (PAC), or any party that creates an encumbrance on shares of a listed company to disclose the event to the stock exchanges and the target company. The disclosure must be made within two working days of the event and must contain:

1. Name of the target company.
2. Names of the exchanges where the target is listed.
3. Details of the promoter or PAC, including shareholding and encumbered portion.
4. Nature of the event (creation, release, or invocation) and the type of encumbrance (pledge, lien, etc.).
5. Reason for the encumbrance.
6. Date of the event.

The revised filing submitted on 20 July 2026 satisfies all these requirements. It updates the earlier disclosure by reflecting the release of the pledged shares, thereby ensuring that market participants have an accurate picture of the promoter’s free‑floating shareholding.

Key facts at a glance

Why this matters for investors

The release of pledged shares has two immediate implications for shareholders of Gujarat Themis Biosyn:

• Increased free‑float: With the 1.51 % of shares no longer encumbered, the proportion of shares available for trading rises marginally, potentially improving liquidity.
• Reduced risk of forced sale: Encumbered shares can be seized by the creditor in case of loan default. By repaying the loan and releasing the pledge, Themis Medicare eliminates that risk, thereby strengthening the promoter’s financial position.

From a regulatory standpoint, the filing demonstrates compliance with SEBI’s transparency norms, which helps maintain market confidence. No dilution occurs because the event does not involve issuance of new shares; it merely alters the status of existing holdings.

Conclusion

Themis Medicare Limited, the promoter of Gujarat Themis Biosyn, has formally disclosed the release of a pledge on 16.5 lakh shares (1.51 % of the target’s equity) on 8 July 2026. The release, undertaken to settle a loan with Jio Credit Limited, leaves the promoter’s shareholding free of any encumbrance. The revised Reg‑31 filing, submitted on 20 July 2026 to both BSE and NSE, satisfies SEBI’s disclosure requirements and provides investors with an updated view of the promoter’s stake and its unencumbered nature. No further regulatory action is pending on this specific event.